Additional biomarkers for pathological complete response in triple negative breast cancer.
作者信息
Weem Khui Wei, Tong Kah Cheong
机构信息
Manchester Royal Infirmary Hospital, Oxford Road, Manchester M13 9WL, UK.
Acute Medical Unit, Stepping Hill Hospital, Stockport, UK.
出版信息
Ther Adv Med Oncol. 2024 Jul 27;16:17588359241267148. doi: 10.1177/17588359241267148. eCollection 2024.
Abstract
摘要
相似文献
1
Additional biomarkers for pathological complete response in triple negative breast cancer.
Ther Adv Med Oncol. 2024 Jul 27;16:17588359241267148. doi: 10.1177/17588359241267148. eCollection 2024.
2
Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy.
Cancer Med. 2023 Feb;12(3):2906-2917. doi: 10.1002/cam4.5207. Epub 2022 Sep 8.
3
Combined immunotherapy for metastatic triple-negative breast cancer based on PD-1/PD-L1 immune checkpoint blocking.
Int Immunopharmacol. 2022 Dec;113(Pt B):109444. doi: 10.1016/j.intimp.2022.109444. Epub 2022 Nov 16.
4
Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer.
J Pers Med. 2023 Mar 15;13(3):526. doi: 10.3390/jpm13030526.
5
Efficacy and safety of PD-1/PD-L1 inhibitors in triple-negative breast cancer: a systematic review and meta-analysis.
Acta Oncol. 2022 Sep;61(9):1105-1115. doi: 10.1080/0284186X.2022.2106795. Epub 2022 Aug 8.
6
New strategies for the management of triple-negative breast cancer.
Curr Opin Obstet Gynecol. 2024 Feb 1;36(1):40-44. doi: 10.1097/GCO.0000000000000927. Epub 2023 Dec 8.
7
Programmed death-ligand 1 (PD-L1) expression predicts response to neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis.
Biomarkers. 2022 Dec;27(8):764-772. doi: 10.1080/1354750X.2022.2112614. Epub 2022 Aug 22.
8
Genomic alterations affecting tumor-infiltrating lymphocytes and PD-L1 expression patterns in triple-negative breast cancer.
J Natl Cancer Inst. 2023 Dec 6;115(12):1586-1596. doi: 10.1093/jnci/djad154.
9
Construction and validation of a gene expression classifier to predict immunotherapy response in primary triple-negative breast cancer.
Commun Med (Lond). 2023 Jul 10;3(1):93. doi: 10.1038/s43856-023-00311-y.
10
Clinical characteristics associated with efficacy and prognosis among patients treated with PD-1/PD-L1 inhibitors for early-stage triple-negative breast cancers: A meta-analysis.
Crit Rev Oncol Hematol. 2024 Apr;196:104309. doi: 10.1016/j.critrevonc.2024.104309. Epub 2024 Feb 28.
本文引用的文献
1
Assessment of novel prognostic biomarkers to predict pathological complete response in patients with non-metastatic triple-negative breast cancer using a window of opportunity design.
Ther Adv Med Oncol. 2024 May 24;16:17588359241248329. doi: 10.1177/17588359241248329. eCollection 2024.
2
Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review.
Int J Mol Sci. 2023 Feb 3;24(3):2969. doi: 10.3390/ijms24032969.
3
A systematic review and meta-analysis of BRCA1/2 mutation for predicting the effect of platinum-based chemotherapy in triple-negative breast cancer.
Breast. 2022 Dec;66:31-39. doi: 10.1016/j.breast.2022.08.012. Epub 2022 Sep 2.
4
Triple-negative breast cancer: promising prognostic biomarkers currently in development.
Expert Rev Anticancer Ther. 2021 Feb;21(2):135-148. doi: 10.1080/14737140.2021.1840984.
5
Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.
Ann Oncol. 2018 Apr 1;29(4):1056-1062. doi: 10.1093/annonc/mdx730.
6
Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women.
J Clin Oncol. 2011 Nov 20;29(33):4373-80. doi: 10.1200/JCO.2010.33.6446. Epub 2011 Oct 17.
Zotero 插件